Children are the hardest hit by malaria – around 70% of those that die are under 5 years of age. Yet typically in drug development, medicines are developed for adults before child-friendly versions are pursued.

MMV and partners are developing and improving access to child-friendly formulations of existing antimalarials for treatment and chemoprevention. We are also developing next-generation medicines for children in parallel with adult formulations.

Go to the portfolio of MMV-supported projects [2] for an overview of medicines with Paediatric formulations.

 Read more about:

• Coartem^®Dispersible [3]
• Pyramax® Granules [4]
• Rectal artesunate [5]
• Sulfadoxine–pyrimethamine and amodiaquine (SPAQ) [6]